Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Mar;99(3):165-74.
doi: 10.1007/s00392-009-0101-6. Epub 2010 Jan 6.

Treatment of small coronary arteries with a paclitaxel-coated balloon catheter

Affiliations
Clinical Trial

Treatment of small coronary arteries with a paclitaxel-coated balloon catheter

Martin Unverdorben et al. Clin Res Cardiol. 2010 Mar.

Abstract

Background: Treatment of lesions in small coronary arteries by percutaneous transluminal coronary intervention is limited by a high recurrence rate. We assessed the use of a paclitaxel-coated balloon in this indication.

Methods: One-hundred eighteen patients with stenoses in small coronary vessels were treated by a paclitaxel-coated balloon (3 microg/mm(2)). The main inclusion criteria encompassed diameter stenosis of > or =70% and < or =22 mm in length with a vessel diameter of 2.25-2.8 mm. Follow-up angiography was performed at scheduled 6-month post-intervention or whenever driven by clinical or electrocardiographic signs of ischemia. The primary endpoint was angiographic in-segment late lumen loss.

Results: Eighty-two of 118 patients (70%) with a vessel diameter of 2.35 +/- 0.19 mm were treated with the drug-coated balloon only, while 32 patients required additional stent deployment. The mean in-segment late lumen loss was 0.28 +/- 0.53 mm. In patients treated with the drug-coated balloon only, the in-segment late lumen loss was 0.16 +/- 0.38 mm. At 12 months, the rate of major adverse cardiac events was 15% which was primarily due to the need for target lesion revascularization in 14 patients (12%). In those with additional bare metal stent implantation geographical mismatch between coated-balloon dilatation and stent implantation was significantly associated with the occurrence of restenosis.

Conclusion: Treatment of coronary stenosis in small coronary vessels with the paclitaxel-coated balloon was well tolerated. It may offer an alternative to the implantation of a drug-eluting stent (ClinicalTrials.gov Identifier: NCT00404144).

PubMed Disclaimer

Similar articles

Cited by

References

    1. JAMA. 2005 Sep 14;294(10):1215-23 - PubMed
    1. Circulation. 2004 Aug 17;110(7):810-4 - PubMed
    1. J Am Coll Cardiol. 2006 Oct 3;48(7):1304-9 - PubMed
    1. Circ Cardiovasc Interv. 2009 Aug;2(4):294-301 - PubMed
    1. J Am Coll Cardiol. 2002 Sep 4;40(5):882-9 - PubMed

Publication types

Associated data

LinkOut - more resources